MiT-RCC includes fusion-driven tumors with <i>TFE3</i> or <i>TFEB</i> rearrangements (translocation RCC, tRCC) and <i>TFEB</i>-amplified RCC. The gene discussed is TFE3; the disease is renal cell carcinoma.